These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 600362)

  • 1. Effect of the dopa decarboxylase inhibitor MK-486 on L-dopa-induced inhibition of prolactin secretion: evidence for CNS participation in the L-dopa effects.
    Szabo M; Nakawatase C; Kovathana N; Frohman LA
    Neuroendocrinology; 1977; 24(1):24-34. PubMed ID: 600362
    [No Abstract]   [Full Text] [Related]  

  • 2. Carbidopa plus L-dopa pretreatment inhibits the prolactin (PRL) response to thyrotropin-releasing hormone and thus cannot distinguish central from pituitary sites of prolactin stimulation.
    Carlson HE
    J Clin Endocrinol Metab; 1986 Jul; 63(1):249-51. PubMed ID: 3086358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Further evidence on the direct action of L-Dopa on prolactin release.
    Donoso AO; Banzán AM; Barcaglioni JC
    Neuroendocrinology; 1974; 15(3-4):236-9. PubMed ID: 4420786
    [No Abstract]   [Full Text] [Related]  

  • 4. The effect of L-dopa with and without decarboxylase inhibitor on growth hormone secretion in children with short stature.
    Fevang FO; Stoa RF; Thorsen T; Aarskog D
    Acta Paediatr Scand; 1977 Jan; 66(1):81-4. PubMed ID: 831384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. L-Dopa inhibits prolactin secretion in proestrous rats.
    Wiggins JF; Fernstrom JD
    Endocrinology; 1977 Aug; 101(2):469-74. PubMed ID: 560295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. L-DOPA and the control of prolactin secretion.
    Frantz AG; Suh HK
    Adv Neurol; 1974; 5():447-56. PubMed ID: 4216257
    [No Abstract]   [Full Text] [Related]  

  • 7. Loss of central nervous system component of dopaminergic inhibition of prolactin secretion in patients with prolactin-secreting pituitary tumors.
    Fine SA; Frohman LA
    J Clin Invest; 1978 Apr; 61(4):973-80. PubMed ID: 659585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of low dose carbidopa/levodopa on prolactin and growth hormone concentrations in patients with breast cancer and in benign breast tumours.
    Jones MK; Ramsay ID; Jenner PG
    Br J Clin Pharmacol; 1978 May; 5(5):425-30. PubMed ID: 656281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of carbidopa and L-dopa combination on the secretion of growth hormone in normal subjects and in patients with Parkinsonism].
    Nurzia A; Vacca U; Pirro R; Cerone G
    Clin Ter; 1975 Aug; 74(3):265-70. PubMed ID: 1227747
    [No Abstract]   [Full Text] [Related]  

  • 10. Stimulatory effect of the dopa-decarboxylase inhibitor Ro 4-4602 on prolactin release; inhibition by l-dopa, metergoline, methysergide and 2-Br-alpha-ergocryptine.
    Pontiroli AE; Castegnaro E; Vettaro MP; Viberti GC; Pozza G
    Acta Endocrinol (Copenh); 1977 Jan; 84(1):36-44. PubMed ID: 318788
    [No Abstract]   [Full Text] [Related]  

  • 11. L-3,4-dihydroxyphenylalanine (L-dopa) as an inhibitor of prolactin release.
    Jimenez AE; Voogt JL; Carr LA
    Endocrinology; 1978 Jan; 102(1):166-74. PubMed ID: 743945
    [No Abstract]   [Full Text] [Related]  

  • 12. [Prevention with sulpiride of the inhibitory effect of L-DOPA on prolactin secretion].
    Rolandi E; Barreca T; Masturzo P; Polleri A
    Boll Soc Ital Biol Sper; 1975 Jun; 51(12):751-4. PubMed ID: 1222097
    [No Abstract]   [Full Text] [Related]  

  • 13. Action of phenytoin, ethosuximide and of the carbidopa-L-dopa association in semi-chronic cobalt-induced epilepsy in the rat.
    Scuvee-Moreau J; Lepot M; Brotchi J; Gerebtzoff MA; Dresse A
    Arch Int Pharmacodyn Ther; 1977 Nov; 230(1):92-9. PubMed ID: 603313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Ineffectiveness of L-DOPA on hyperprolactinemia induced with sulpiride].
    Barreca T; Rolandi E; Masturzo P; Gianrossi R; Cicchetti V
    Boll Soc Ital Biol Sper; 1975 Jun; 51(12):755-8. PubMed ID: 1222098
    [No Abstract]   [Full Text] [Related]  

  • 15. Integrity of central dopaminergic system in women with postpartum hyperprolactinemia.
    Rao R; Scommegna A; Frohman LA
    Am J Obstet Gynecol; 1982 Aug; 143(8):883-7. PubMed ID: 7102764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of VB6 on L-DOPA decarboxylase activity in the organs of rats given peripheral L-DOPA decarboxylase inhibitors (author's transl)].
    Yoshimine N; Kuzuya F; Mori K; Sakamoto N
    Nihon Ronen Igakkai Zasshi; 1978 Nov; 15(6):566-73. PubMed ID: 732010
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of pyridoxine on the depletion of tissue pyridoxal phosphate by carbidopa.
    Airoldi L; Watkins CJ; Wiggins JF; Wurtman RJ
    Metabolism; 1978 Jul; 27(7):771-9. PubMed ID: 661563
    [No Abstract]   [Full Text] [Related]  

  • 18. [Somatosensory evoked potentials in patients with parkinsonism during L-dopa decarboxylase inhibitor treatment].
    Koziel H; Kuran W; Zakrzewska F
    Neurol Neurochir Pol; 1977; 11(1):73-80. PubMed ID: 840365
    [No Abstract]   [Full Text] [Related]  

  • 19. L-dihydroxyphenylalanine methyl ester is a potent competitive antagonist of the L-dihydroxyphenylalanine-induced facilitation of the evoked release of endogenous norepinephrine from rat hypothalamic slices.
    Goshima Y; Nakamura S; Misu Y
    J Pharmacol Exp Ther; 1991 Aug; 258(2):466-71. PubMed ID: 1865350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [HGH secretion after oral application of L-dopa and L-carbidopa (author's transl)].
    Schönberger W; Ziegler R; Brodt B; Grimm W
    Eur J Pediatr; 1976 Jun; 122(3):195-200. PubMed ID: 1278188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.